Review
. 2009 Feb;11(1).
doi: 10.1186/bcr2209.

Are we HER-ting for innovation in neoadjuvant breast cancer trial design?

Natasa Snoj 1 Philippe L Bedard  Evandro de Azambuja  Fatima Cardoso  Martine Piccart  
Affiliations
  • PMID: 19216727
  •     58 References
  •     3 citations

Abstract

Through the use of surrogate markers of efficacy, neoadjuvant studies may facilitate the implementation of new treatments into clinical practice. However, disease-free survival is the current standard outcome endpoint for registration of a novel treatment. The coupling of smaller neoadjuvant 'proof of principle' studies with larger adjuvant registration trials offers the promise of speeding up the time to market of new therapies. Clever new designs, such as the 'biological window' and 'learn on the way', can provide valuable insight regarding mechanisms of action and resistance of these novel drugs by identifying patients who are most likely to respond to a novel therapy early in the drug development process. Using the ongoing neoadjuvant trials with HER2 (human epidermal growth factor receptor 2)-directed therapy as a paradigm, this article discusses recent innovations in study design and the challenges of conducting translational research in the neoadjuvant setting.

Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial.
M Untch, R D Gelber, +26 authors, HERA Study Team.
Ann Oncol, 2008 Feb 26; 19(6). PMID: 18296421
Prediction of clinicopathologic response of breast cancer to primary chemotherapy at contrast-enhanced MR imaging: initial clinical results.
Anwar R Padhani, Carmel Hayes, +5 authors, Janet E Husband.
Radiology, 2006 Mar 18; 239(2). PMID: 16543585
Inflammatory breast carcinoma and noninflammatory locally advanced breast carcinoma: distinct clinicopathologic entities?
William F Anderson, Kenneth C Chu, Shine Chang.
J Clin Oncol, 2003 Jun 14; 21(12). PMID: 12805323
FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets.
Martin H Cohen, Grant A Williams, +2 authors, Richard Pazdur.
Oncologist, 2003 Aug 05; 8(4). PMID: 12897327
Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses.
M Baum, A Buzdar, +5 authors, ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialists' Group.
Cancer, 2003 Oct 30; 98(9). PMID: 14584060
Highly Cited.
Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.
Giuseppe Giaccone, Roy S Herbst, +15 authors, David H Johnson.
J Clin Oncol, 2004 Mar 03; 22(5). PMID: 14990632
Highly Cited.
Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.
Roy S Herbst, Giuseppe Giaccone, +14 authors, David H Johnson.
J Clin Oncol, 2004 Mar 03; 22(5). PMID: 14990633
Highly Cited.
Review: polymerase chain reaction detection of micrometastases and circulating tumor cells: application to melanoma, prostate, and thyroid carcinomas.
R A Ghossein, L Carusone, S Bhattacharya.
Diagn Mol Pathol, 2000 Jan 05; 8(4). PMID: 10617272
Review.
Positron emission tomography using [(18)F]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy.
I C Smith, A E Welch, +10 authors, P F Sharp.
J Clin Oncol, 2000 Apr 14; 18(8). PMID: 10764428
Positron emission tomography using [(18)F]Fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer.
M Schelling, N Avril, +8 authors, M Schwaiger.
J Clin Oncol, 2000 Apr 14; 18(8). PMID: 10764429
Highly Cited.
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
D J Slamon, B Leyland-Jones, +9 authors, L Norton.
N Engl J Med, 2001 Mar 15; 344(11). PMID: 11248153
Highly Cited.
MRI phenotype is associated with response to doxorubicin and cyclophosphamide neoadjuvant chemotherapy in stage III breast cancer.
L Esserman, E Kaplan, +8 authors, N Hylton.
Ann Surg Oncol, 2001 Jul 18; 8(6). PMID: 11456056
Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer.
I Craig Henderson, Donald A Berry, +16 authors, Larry Norton.
J Clin Oncol, 2003 Mar 15; 21(6). PMID: 12637460
Highly Cited.
Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer:National Surgical Adjuvant Breast and Bowel Project Protocol B-27.
Harry D Bear, Stewart Anderson, +11 authors, Norman Wolmark.
J Clin Oncol, 2006 Apr 12; 24(13). PMID: 16606972
Highly Cited.
Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.
Soonmyung Paik, Gong Tang, +11 authors, Norman Wolmark.
J Clin Oncol, 2006 May 25; 24(23). PMID: 16720680
Highly Cited.
Predictive and prognostic value of peripheral blood cytokeratin-19 mRNA-positive cells detected by real-time polymerase chain reaction in node-negative breast cancer patients.
Nikos Xenidis, Maria Perraki, +13 authors, Dimitris Mavroudis.
J Clin Oncol, 2006 Jun 14; 24(23). PMID: 16769987
A highly specific real-time RT-PCR method for the quantitative determination of CK-19 mRNA positive cells in peripheral blood of patients with operable breast cancer.
Aliki Stathopoulou, Maria Ntoulia, +5 authors, Evi S Lianidou.
Int J Cancer, 2006 May 19; 119(7). PMID: 16708381
Impact and perceptions of mandatory tumor biopsies for correlative studies in clinical trials of novel anticancer agents.
Mark Agulnik, Amit M Oza, Gregory R Pond, Lillian L Siu.
J Clin Oncol, 2006 Oct 20; 24(30). PMID: 17050865
Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial.
Henri Roché, Pierre Fumoleau, +17 authors, Bernard Asselain.
J Clin Oncol, 2006 Nov 23; 24(36). PMID: 17116941
Highly Cited.
Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen.
Aman U Buzdar, Vicente Valero, +13 authors, Gabriel N Hortobagyi.
Clin Cancer Res, 2007 Jan 04; 13(1). PMID: 17200359
Highly Cited.
Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer.
Mitch Dowsett, Ian E Smith, +8 authors, IMPACT Trialists Group.
J Natl Cancer Inst, 2007 Jan 18; 99(2). PMID: 17228000
Highly Cited.
Keeping faith with trial volunteers.
Martine Piccart, Aron Goldhirsch, +7 authors, Alan Coates.
Nature, 2007 Mar 09; 446(7132). PMID: 17344833
Achieving higher pathological complete response rates in HER-2-positive patients with induction chemotherapy without trastuzumab in operable breast cancer.
Frédérique Penault-Llorca, Catherine Abrial, +7 authors, Philippe Chollet.
Oncologist, 2007 May 02; 12(4). PMID: 17470681
Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system.
Clifford A Hudis, William E Barlow, +8 authors, Jo Anne Zujewski.
J Clin Oncol, 2007 May 22; 25(15). PMID: 17513820
Highly Cited.
Leuprorelin acetate every-3-months depot versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant treatment in premenopausal patients with node-positive breast cancer: the TABLE study.
Peter Schmid, Michael Untch, +8 authors, Kurt Possinger.
J Clin Oncol, 2007 Jun 20; 25(18). PMID: 17577027
Multicenter phase II trial of neoadjuvant therapy with trastuzumab, docetaxel, and carboplatin for human epidermal growth factor receptor-2-overexpressing stage II or III breast cancer: results of the GETN(A)-1 trial.
Bruno P Coudert, Remy Largillier, +12 authors, Moïse Namer.
J Clin Oncol, 2007 May 23; 25(19). PMID: 17515572
Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy.
W Fraser Symmans, Florentia Peintinger, +11 authors, Lajos Pusztai.
J Clin Oncol, 2007 Sep 06; 25(28). PMID: 17785706
Highly Cited.
Tumor mRNA expression profiles predict responses to chemotherapy.
John D Minna, Luc Girard, Yang Xie.
J Clin Oncol, 2007 Oct 02; 25(28). PMID: 17906194
Review.
American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer.
Lyndsay Harris, Herbert Fritsche, +7 authors, American Society of Clinical Oncology.
J Clin Oncol, 2007 Oct 24; 25(33). PMID: 17954709
Highly Cited. Review.
Preoperative chemotherapy for breast cancer: miracle or mirage?
Clifford Hudis, Shanu Modi.
JAMA, 2007 Dec 13; 298(22). PMID: 18073362
MRI evaluation of pathologically complete response and residual tumors in breast cancer after neoadjuvant chemotherapy.
Jeon Hor Chen, Byron Feig, +6 authors, Min Ying Su.
Cancer, 2007 Nov 15; 112(1). PMID: 18000804
Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27.
Priya Rastogi, Stewart J Anderson, +15 authors, Norman Wolmark.
J Clin Oncol, 2008 Feb 09; 26(5). PMID: 18258986
Highly Cited.
Locally advanced and inflammatory breast cancer.
Stephen Chia, Sandra M Swain, David R Byrd, David A Mankoff.
J Clin Oncol, 2008 Feb 09; 26(5). PMID: 18258987
Review.
Statement of the science concerning locoregional treatments after preoperative chemotherapy for breast cancer: a National Cancer Institute conference.
Thomas A Buchholz, Constance D Lehman, +11 authors, Eleftherios P Mamounas.
J Clin Oncol, 2008 Feb 09; 26(5). PMID: 18258988
Review.
Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease.
Julie R Gralow, Harold J Burstein, +8 authors, Eric P Winer.
J Clin Oncol, 2008 Feb 09; 26(5). PMID: 18258991
Highly Cited. Review.
Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial.
Gunter von Minckwitz, Sherko Kümmel, +11 authors, German Breast Group.
J Natl Cancer Inst, 2008 Apr 10; 100(8). PMID: 18398097
Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis.
Rinaa S Punglia, Harold J Burstein, Eric P Winer, Jane C Weeks.
J Natl Cancer Inst, 2008 May 01; 100(9). PMID: 18445827    Free PMC article.
Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy.
Paul L Nguyen, Alphonse G Taghian, +7 authors, Jay R Harris.
J Clin Oncol, 2008 Apr 17; 26(14). PMID: 18413639
Highly Cited.
The use of alternate, non-cross-resistant adjuvant chemotherapy on the basis of pathologic response to a neoadjuvant doxorubicin-based regimen in women with operable breast cancer: long-term results from a prospective randomized trial.
Eva Thomas, Frankie A Holmes, +9 authors, Gabriel N Hortobagyi.
J Clin Oncol, 2004 Jun 16; 22(12). PMID: 15197190
Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases.
W Jeffrey Allard, Jeri Matera, +6 authors, Leon W M M Terstappen.
Clin Cancer Res, 2004 Oct 27; 10(20). PMID: 15501967
Highly Cited.
Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute.
G Bonadonna, P Valagussa, +4 authors, M Zambetti.
J Clin Oncol, 1998 Jan 24; 16(1). PMID: 9440728
Highly Cited.
Effect of preoperative chemotherapy on the outcome of women with operable breast cancer.
B Fisher, J Bryant, +13 authors, H D Bear.
J Clin Oncol, 1998 Aug 15; 16(8). PMID: 9704717
Highly Cited.
Neoadjuvant chemotherapy of locally advanced breast cancer: predicting response with in vivo (1)H MR spectroscopy--a pilot study at 4 T.
Sina Meisamy, Patrick J Bolan, +8 authors, Michael Garwood.
Radiology, 2004 Nov 02; 233(2). PMID: 15516615
Targeted imaging using ultrasound contrast agents. Progess and opportunities for clinical and research applications.
Susannah H Bloch, Paul A Dayton, Katherine W Ferrara.
IEEE Eng Med Biol Mag, 2004 Nov 30; 23(5). PMID: 15565796
Review.
In vivo chemosensitivity-adapted preoperative chemotherapy in patients with early-stage breast cancer: the GEPARTRIO pilot study.
G von Minckwitz, J-U Blohmer, +10 authors, German Breast Group.
Ann Oncol, 2004 Dec 16; 16(1). PMID: 15598939
Detection of CK-19 mRNA-positive cells in the peripheral blood of breast cancer patients with histologically and immunohistochemically negative axillary lymph nodes.
E N Stathopoulos, E Sanidas, +6 authors, V Georgoulias.
Ann Oncol, 2005 Jan 26; 16(2). PMID: 15668277
Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis.
Davide Mauri, Nicholas Pavlidis, John P A Ioannidis.
J Natl Cancer Inst, 2005 Feb 03; 97(3). PMID: 15687361
Highly Cited.
Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival.
Mitch Dowsett, Ian E Smith, +11 authors, IMPACT Trialists.
Clin Cancer Res, 2005 Feb 11; 11(2 Pt 2). PMID: 15701892
Residual tumor uptake of [99mTc]-sestamibi after neoadjuvant chemotherapy for locally advanced breast carcinoma predicts survival.
Lisa K Dunnwald, Julie R Gralow, +6 authors, David A Mankoff.
Cancer, 2005 Jan 08; 103(4). PMID: 15637688
Gene expression profiling identifies molecular subtypes of inflammatory breast cancer.
François Bertucci, Pascal Finetti, +9 authors, Daniel Birnbaum.
Cancer Res, 2005 Mar 23; 65(6). PMID: 15781628
Phase III randomized trial of doxorubicin and docetaxel versus doxorubicin and cyclophosphamide as primary medical therapy in women with breast cancer: an anglo-celtic cooperative oncology group study.
T R Jeffry Evans, Ann Yellowlees, +12 authors, Janine L Mansi.
J Clin Oncol, 2005 Apr 30; 23(13). PMID: 15860854
MRI measurements of breast tumor volume predict response to neoadjuvant chemotherapy and recurrence-free survival.
Savannah C Partridge, Jessica E Gibbs, +7 authors, Nola M Hylton.
AJR Am J Roentgenol, 2005 May 24; 184(6). PMID: 15908529
Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer.
Aman U Buzdar, Nuhad K Ibrahim, +17 authors, Gabriel N Hortobagyi.
J Clin Oncol, 2005 Mar 02; 23(16). PMID: 15738535
Highly Cited.
Breast cancer molecular subtypes respond differently to preoperative chemotherapy.
Roman Rouzier, Charles M Perou, +13 authors, Lajos Pusztai.
Clin Cancer Res, 2005 Aug 24; 11(16). PMID: 16115903
Highly Cited.
Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes.
Matthew P Goetz, James M Rae, +10 authors, James N Ingle.
J Clin Oncol, 2005 Dec 20; 23(36). PMID: 16361630
Highly Cited.
Imaging in breast cancer: diffuse optics in breast cancer: detecting tumors in pre-menopausal women and monitoring neoadjuvant chemotherapy.
Bruce J Tromberg, Albert Cerussi, +5 authors, Rita Mehta.
Breast Cancer Res, 2006 Feb 07; 7(6). PMID: 16457705    Free PMC article.
Review.
Phase II, open-label, randomized study (SIGN) of single-agent gefitinib (IRESSA) or docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non-small-cell lung cancer.
Tanja Cufer, Eduard Vrdoljak, +3 authors, SIGN Study Group.
Anticancer Drugs, 2006 Mar 22; 17(4). PMID: 16549997
Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].
Masahiro Fukuoka, Seiji Yano, +17 authors, José Baselga.
J Clin Oncol, 2003 May 16; 21(12). PMID: 12748244
Highly Cited.
Utility of DNA postreplication repair protein Rad6B in neoadjuvant chemotherapy response.
Malathy P V Shekhar, Laura A Biernat, +3 authors, Daniel W Visscher.
Med Oncol, 2009 May 26; 27(2). PMID: 19466589
Reciprocal regulation of annexin A2 and EGFR with Her-2 in Her-2 negative and herceptin-resistant breast cancer.
Praveenkumar K Shetty, Sanjay I Thamake, +2 authors, Jamboor K Vishwanatha.
PLoS One, 2012 Sep 08; 7(9). PMID: 22957061    Free PMC article.
Benefit of the addition of hormone therapy to neoadjuvant anthracycline-based chemotherapy for breast cancer: comparison of predicted and observed pCR.
Daniele Generali, Silvia Paola Corona, +6 authors, Albane Frati.
J Cancer Res Clin Oncol, 2018 Jan 19; 144(3). PMID: 29344722